AU2008227100B2 - Pyridazinone derivatives useful as glucan synthase inhibitors - Google Patents

Pyridazinone derivatives useful as glucan synthase inhibitors Download PDF

Info

Publication number
AU2008227100B2
AU2008227100B2 AU2008227100A AU2008227100A AU2008227100B2 AU 2008227100 B2 AU2008227100 B2 AU 2008227100B2 AU 2008227100 A AU2008227100 A AU 2008227100A AU 2008227100 A AU2008227100 A AU 2008227100A AU 2008227100 B2 AU2008227100 B2 AU 2008227100B2
Authority
AU
Australia
Prior art keywords
compound
alkyl
candida
spp
pct
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2008227100A
Other languages
English (en)
Other versions
AU2008227100A1 (en
Inventor
Robert G. Aslanian
Jianhua Cao
Robert Jason Herr
David Won-Shik Kim
Rongze Kuang
Pauline C. Ting
Heping Wu
Jinhai Yang
Gang Zhou
Nicolas Zorn
Andrew John Zych
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme LLC
Curia Global Inc
Original Assignee
Merck Sharp and Dohme Ltd
Albany Molecular Research Inc
Merck Sharp and Dohme LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp and Dohme Ltd, Albany Molecular Research Inc, Merck Sharp and Dohme LLC filed Critical Merck Sharp and Dohme Ltd
Publication of AU2008227100A1 publication Critical patent/AU2008227100A1/en
Assigned to MERCK SHARP & DOHME CORP., ALBANY MOLECULAR RESEARCH, INC. reassignment MERCK SHARP & DOHME CORP. Alteration of Name(s) of Applicant(s) under S113 Assignors: ALBANY MOLECULAR RESEARCH, INC., SCHERING CORPORATION
Application granted granted Critical
Publication of AU2008227100B2 publication Critical patent/AU2008227100B2/en
Priority to AU2014201996A priority Critical patent/AU2014201996A1/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D515/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D515/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains four or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
AU2008227100A 2007-03-15 2008-03-12 Pyridazinone derivatives useful as glucan synthase inhibitors Ceased AU2008227100B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2014201996A AU2014201996A1 (en) 2007-03-15 2014-04-08 Pyridazinone derivatives useful as glucan synthase inhibitors

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US91817107P 2007-03-15 2007-03-15
US60/918,171 2007-03-15
PCT/US2008/003257 WO2008115381A1 (en) 2007-03-15 2008-03-12 Pyridazinone derivatives useful as glucan synthase inhibitors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2014201996A Division AU2014201996A1 (en) 2007-03-15 2014-04-08 Pyridazinone derivatives useful as glucan synthase inhibitors

Publications (2)

Publication Number Publication Date
AU2008227100A1 AU2008227100A1 (en) 2008-09-25
AU2008227100B2 true AU2008227100B2 (en) 2014-01-09

Family

ID=39525788

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2008227100A Ceased AU2008227100B2 (en) 2007-03-15 2008-03-12 Pyridazinone derivatives useful as glucan synthase inhibitors

Country Status (18)

Country Link
US (1) US8232274B2 (enExample)
EP (2) EP2586778A3 (enExample)
JP (3) JP5147866B2 (enExample)
KR (1) KR20100049500A (enExample)
CN (1) CN101730692A (enExample)
AR (1) AR065721A1 (enExample)
AU (1) AU2008227100B2 (enExample)
BR (1) BRPI0809238A2 (enExample)
CA (1) CA2680583A1 (enExample)
CL (1) CL2008000725A1 (enExample)
CO (1) CO6220966A2 (enExample)
EC (1) ECSP099634A (enExample)
IL (1) IL200906A0 (enExample)
MX (1) MX2009009948A (enExample)
PE (1) PE20081882A1 (enExample)
RU (1) RU2009137946A (enExample)
TW (1) TW200902516A (enExample)
WO (1) WO2008115381A1 (enExample)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010521463A (ja) * 2007-03-15 2010-06-24 シェーリング コーポレイション グルカンシンターゼの阻害剤として有用なピペラジン置換ビリダジノン誘導体
EP2137162B1 (en) 2007-03-15 2018-08-01 Novartis AG Organic compounds and their uses
CA2697551C (en) * 2007-09-20 2013-03-12 Irm Llc Piperidine derivatives as modulators of gpr119 activity
JP5627574B2 (ja) 2008-06-03 2014-11-19 インターミューン， インコーポレイテッド 炎症性および線維性疾患を治療するための化合物および方法
US20100041663A1 (en) 2008-07-18 2010-02-18 Novartis Ag Organic Compounds as Smo Inhibitors
US20120088769A1 (en) * 2010-10-11 2012-04-12 Axikin Pharmaceuticals, Inc. Salts of arylsulfonamide ccr3 antagonists
FI20115234A0 (fi) 2011-03-08 2011-03-08 Biotie Therapies Corp Uusia pyridatsinoni- ja pyridoniyhdisteitä
GB201111705D0 (en) 2011-07-07 2011-08-24 Takeda Pharmaceutical Compounds and their use
GB201111704D0 (en) 2011-07-07 2011-08-24 Takeda Pharmaceutical Novel compounds
JO3115B1 (ar) * 2011-08-22 2017-09-20 Takeda Pharmaceuticals Co مركبات بيريدازينون واستخدامها كمثبطات daao
AP2014007637A0 (en) 2011-11-15 2014-05-31 Takeda Pharmaceutical Dihydroxy aromatic heterocyclic compound
CN104379563B (zh) * 2012-04-10 2018-12-21 加利福尼亚大学董事会 用于治疗癌症的组合物和方法
AU2013203000B9 (en) 2012-08-10 2017-02-02 Lantheus Medical Imaging, Inc. Compositions, methods, and systems for the synthesis and use of imaging agents
CN103664795B (zh) * 2012-09-06 2017-10-03 华东理工大学 哒嗪酮类化合物及其用途
AR092742A1 (es) 2012-10-02 2015-04-29 Intermune Inc Piridinonas antifibroticas
JP6310464B2 (ja) 2012-10-05 2018-04-11 コーニンクレッカ フィリップス エヌ ヴェＫｏｎｉｎｋｌｉｊｋｅ Ｐｈｉｌｉｐｓ Ｎ．Ｖ． 改善されたｘ線画像を供する医療撮像システム及び方法
GB201222711D0 (en) * 2012-12-17 2013-01-30 Takeda Pharmaceutical Novel compounds
US10070649B2 (en) 2013-01-30 2018-09-11 Agrofresh Inc. Volatile applications against pathogens
US11039617B2 (en) 2013-01-30 2021-06-22 Agrofresh Inc. Large scale methods of uniformly coating packaging surfaces with a volatile antimicrobial to preserve food freshness
CA2922567A1 (en) * 2013-08-26 2015-03-05 Purdue Pharma L.P. Azaspiro[4.5]decane derivatives and use thereof
US10233195B2 (en) 2014-04-02 2019-03-19 Intermune, Inc. Anti-fibrotic pyridinones
CA2946163A1 (en) * 2014-04-24 2015-10-29 Hexima Limited Agents and methods of treatment
NZ745681A (en) 2016-03-07 2022-05-27 Agrofresh Inc Synergistic methods of using benzoxaborole compounds and preservative gases as an antimicrobial for crops
EP3596043B1 (en) 2017-03-15 2025-12-03 Lunella Biotech, Inc. Mitoriboscins: mitochondrial-based therapeutics targeting cancer cells, bacteria, and pathogenic yeast
US20210101874A1 (en) 2017-04-03 2021-04-08 Syngenta Participations Ag Microbiocidal oxadiazole derivatives
AU2018334290A1 (en) 2017-09-18 2020-04-02 Goldfinch Bio, Inc. Pyridazinones and methods of use thereof
CN109912476A (zh) * 2019-03-27 2019-06-21 南通宝凯化工有限公司 一种异丙氨基磺酰氯的生产工艺
TW202115042A (zh) * 2019-06-21 2021-04-16 大陸商江蘇豪森藥業集團有限公司 芳基磷氧化物類衍生物抑制劑、其製備方法和應用
US12509444B2 (en) * 2019-12-06 2025-12-30 Plexxikon Inc. Compounds and methods for CD73 modulation and indications therefor
CN115551862B (zh) 2020-04-30 2024-04-12 吉利德科学公司 肽基精氨酸脱亚胺酶的大环抑制剂
JPWO2023204124A1 (enExample) * 2022-04-20 2023-10-26

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH04235975A (ja) * 1991-01-21 1992-08-25 Nissan Chem Ind Ltd ピリダジノン誘導体および害虫防除剤
CA2482151A1 (en) * 2002-04-12 2003-11-27 Bayer Healthcare Ag Substituted 2-phenyl-3(2h)-pyridazinones

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS565734B2 (enExample) * 1973-02-28 1981-02-06
DE3048487A1 (de) * 1980-12-22 1982-07-29 Cassella Ag, 6000 Frankfurt Basisch substituierte pyridazine, ihre herstellung und ihre verwendung
ES8601972A1 (es) 1985-02-28 1985-11-16 Abello Quimicos Farma Prod Sa Procedimiento de obtencion de 1,2-diazin-3 (2h)-onas con interes farmaceutico
GB2256587A (en) 1991-06-11 1992-12-16 American Cyanamid Co Acetazolamide in sustained release form
HU227237B1 (en) * 2001-09-27 2010-12-28 Egis Gyogyszergyar Nyilvanosan Muekoedoe Reszvenytarsasag Substituted alkylpyridazinone derivatives, process for their preparation, pharmaceutical compositions containing them
EP1479681A4 (en) * 2002-01-31 2006-05-10 Daiichi Seiyaku Co IMIDAZO (1,2-a) pyridine
US20050209278A1 (en) * 2002-04-25 2005-09-22 Mcdonald Joseph J Piperidinyl- and piperazinyl-sulfonylmethyl hydroxamic acids and their use as protease inhibitors
UA77526C2 (en) * 2002-06-07 2006-12-15 Sanofi Aventis Substituted derivatives of 1-piperazineacylpiperidine, a method for the preparation thereof and their use in therapy
NZ547481A (en) * 2003-11-19 2009-12-24 Array Biopharma Inc Heterocyclic inhibitors of mek and methods of use thereof
WO2005117909A2 (en) * 2004-04-23 2005-12-15 Exelixis, Inc. Kinase modulators and methods of use
GB0524991D0 (en) * 2005-12-08 2006-01-18 Ge Healthcare Ltd Novel imaging agents for fibrosis
WO2007130383A2 (en) * 2006-04-28 2007-11-15 Northwestern University Compositions and treatments using pyridazine compounds and secretases
JP2010521463A (ja) * 2007-03-15 2010-06-24 シェーリング コーポレイション グルカンシンターゼの阻害剤として有用なピペラジン置換ビリダジノン誘導体

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH04235975A (ja) * 1991-01-21 1992-08-25 Nissan Chem Ind Ltd ピリダジノン誘導体および害虫防除剤
CA2482151A1 (en) * 2002-04-12 2003-11-27 Bayer Healthcare Ag Substituted 2-phenyl-3(2h)-pyridazinones

Also Published As

Publication number Publication date
EP2586778A3 (en) 2013-07-31
JP5147866B2 (ja) 2013-02-20
EP2586778A2 (en) 2013-05-01
US20090170861A1 (en) 2009-07-02
TW200902516A (en) 2009-01-16
JP2014051529A (ja) 2014-03-20
MX2009009948A (es) 2009-09-24
RU2009137946A (ru) 2011-04-20
WO2008115381A1 (en) 2008-09-25
JP2013014622A (ja) 2013-01-24
EP2137179A1 (en) 2009-12-30
ECSP099634A (es) 2009-10-30
CN101730692A (zh) 2010-06-09
CA2680583A1 (en) 2008-09-25
CO6220966A2 (es) 2010-11-19
KR20100049500A (ko) 2010-05-12
AU2008227100A1 (en) 2008-09-25
BRPI0809238A2 (pt) 2014-09-09
AR065721A1 (es) 2009-06-24
IL200906A0 (en) 2010-05-17
US8232274B2 (en) 2012-07-31
CL2008000725A1 (es) 2008-11-14
EP2137179B1 (en) 2015-09-02
JP2010521461A (ja) 2010-06-24
PE20081882A1 (es) 2008-12-27

Similar Documents

Publication Publication Date Title
US8232274B2 (en) Pyridazinone derivatives useful as glucan synthase inhibitors
EP3402799B1 (en) Heterocyclic compounds as rsv inhibitors
EP2217611B1 (en) Novel modulators of cell cycle checkpoints and their use in combination with checkpoint kinase inhibitors
US8022088B2 (en) Substituted bicyclic and tricyclic thrombin receptor antagonists
JP5241834B2 (ja) プロテインキナーゼ阻害剤としての複素環アミド化合物
EP3129380B1 (en) Spiro[3h-indole-3,2'-pyrrolidin]-2(1h)-one derivatives and their use as mdm2-p53 inhibitors
EP2819996B1 (en) 6-alkynyl pyridines as smac mimetics
AU2008282885A1 (en) Anti-mitotic agent and aurora kinase inhibitor combination as anti-cancer treatment
CA3071143A1 (en) Novel compounds
CA2680587A1 (en) Piperazine-substituted pyridazinone derivatives useful as glucan synthase inhibitors
US20070232635A1 (en) Monocyclic and bicyclic himbacine derivatives useful as thrombin receptor antagonists
CA2956129A1 (en) New spiro[3h-indole-3,2'-pyrrolidin]-2(1h)-one compounds and derivatives as mdm2-p53 inhibitors
KR20110033239A (ko) 단백질 키나제 억제제
KR20110039278A (ko) 단백질 키나제 억제제
EP3157922B1 (en) Pyrazolo-pyridine derivatives as kinase inhibitors
WO2009097233A9 (en) Imidazopyrazines as protein kinase inhibitors
US7888369B2 (en) Oxazoloisoquinoline derivatives as thrombin receptor antagonists
AU2020413555B2 (en) PD-L1 antagonist compound
CN116836167B (zh) 咪唑并[1,2-a]吡嗪或吡唑并[1,5-a]嘧啶衍生物及其用途
AU2014201996A1 (en) Pyridazinone derivatives useful as glucan synthase inhibitors
CN116848103A (zh) 高活性hpk1激酶抑制剂
CN102869663A (zh) 吡唑并吡嗪激酶抑制剂
CA3000063C (en) Spiro[3h-indole-3,2'-pyrrolidin]-2(1h)-one compounds and derivatives as mdm2-p53 inhibitors
HK30089209A2 (en) Hpk1 kinase inhibitor compound
HK30089210A2 (en) A highly active wnt pathway inhibitor compound

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired